TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report

Ziqing Wang; Weiyi Liu; Dehao Wang; Erpeng Yang; Yujin Li; Yumeng Li; Yan Sun; Mingjing Wang; Yan Lv; Xiaomei Hu

doi:10.3390/jcm11226615

TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report

J Clin Med. 2022 Nov 8;11(22):6615. doi: 10.3390/jcm11226615.

Authors

Ziqing Wang^{1

2}, Weiyi Liu¹, Dehao Wang^{1

2}, Erpeng Yang^{1

3}, Yujin Li^{1

3}, Yumeng Li^{1

3}, Yan Sun^{1

2}, Mingjing Wang¹, Yan Lv¹, Xiaomei Hu¹

Affiliations

¹ Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
² Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China.
³ Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China.

Abstract

Thrombosis is a common complication of myeloproliferative neoplasm (MPN), and it is a major cause of disability and death. With the development of next-generation gene-sequencing technology, the relationship between non-driver mutations and thrombotic risk factors has also attracted considerable attention. To analyze the risk factors of thrombosis in patients with essential thrombocythemia (ET) and polycythemia vera (PV), we retrospectively analyzed the clinical data of 125 MPN patients (75 ET and 50 PV) and performed a multivariate analysis of the risk factors of thrombosis using a Cox proportional risk model. Among the 125 patients, 35 (28.0%) had thrombotic events, and the incidence of thrombotic events was 21.3% and 38.0% in ET and PV patients, respectively. In ET patients, the multivariate analysis showed that a TET2 mutation and history of remote thrombosis were independent risk factors for thrombosis in ET patients, with an HR of 4.1 (95% CI: 1.40-12.01; p = 0.01) for TET2 mutation and 6.89 (95% CI: 1.45-32.68; p = 0.015) for a history of remote thrombosis. In PV patients, the multivariate analysis presented the neutrophil-to-lymphocyte ratio (NLR) (HR: 4.77, 95% CI: 1.33-17.16; p = 0.017) and a history of remote thrombosis (HR: 1.67, 95% CI: 1.03-1.32; p = 0.014) as independent risk factors for thrombosis, with no significant change in the risk of thrombosis in patients with TET2 mutations. A further analysis of the clinical characteristics and coagulation occurring in ET patients with a TET2 mutation revealed that the values of age and D-dimer were significantly higher and antithrombin III was significantly lower in TET2-mutated ET patients compared to TET2-unmutated patients. In summary, TET2 mutation may be more valuable in predicting thrombosis in ET patients than in PV patients. ET patients with a TET2 mutation are older and present differences in coagulation compared to TET2-unmutated patients.

Keywords: TET2 mutation; clinical characteristics; essential thrombocythemia; polycythaemia vera; risk factors; thrombosis.

Abstract

Grants and funding